Trifluoperazine inhibits the MgATPase activity and in vitro motility of conventional and unconventional myosins.
D000199:Actins / Q000378:metabolism; D000818:Animals; D017301:Ca(2+) Mg(2+)-ATPase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002147:Calmodulin / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D000070559:Gizzard, Non-avian / Q000737:chemistry; D015879:Myosin Subfragments / Q000378:metabolism*; D024462:Myosin Type II / Q000378:metabolism; D024701:Myosin Type V / Q000378:metabolism; D024507:Nonmuscle Myosin Type IIA / Q000378:metabolism; D011817:Rabbits; D014268:Trifluoperazine / Q000494:pharmacology*; D014421:Turkey
D000199:Actins; D002147:Calmodulin; D004791:Enzyme Inhibitors; D015879:Myosin Subfragments; D014268:Trifluoperazine; D017301:Ca(2+) Mg(2+)-ATPase; D024462:Myosin Type II; D024701:Myosin Type V; D024507:Nonmuscle Myosin Type IIA